AJHE2307 - CME/CMLE - Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy Report from the 2021 SH/EAHP Workshop-Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy Report from the 2021 SH/EAHP Workshop

Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy Report from the 2021 SH/EAHP Workshop

Back to course

Pdf Summary

The review article discusses phenotypic and genotypic infidelity in B-cell neoplasms, focusing on lineage switch and aberrant antigen expression, specifically following targeted therapy. It covers cases of B-cell acute lymphoblastic leukemia and mature B-cell neoplasms, highlighting lineage switches and unexpected antigen expression changes. The impact of environmental factors and targeted therapies on driving lineage switch is explored, alongside molecular mechanisms like alterations in transcription factors. The complexity of B-cell malignancies and the importance of understanding lineage anomalies for accurate diagnosis and treatment selection are emphasized. Additionally, the document delves into aberrant T-cell antigen expression in various types of B-cell lymphomas, discussing the association of CD5 expression, mechanisms underlying aberrant antigen expression, and the significance of lineage infidelity for diagnosis and management. The review underscores the need for a combined phenotypic and genomic approach for accurate diagnosis and treatment of B-cell malignancies with lineage anomalies, highlighting the implications of antigen loss and aberrant expression in these diseases.

Keywords

B-cell neoplasms

phenotypic infidelity

genotypic infidelity

lineage switch

aberrant antigen expression

targeted therapy

B-cell acute lymphoblastic leukemia

mature B-cell neoplasms

environmental factors

molecular mechanisms